[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III data forAlecensa(early-stage lung cancer) andOcrevus(subcutaneous injection; multiple sclerosis)Positive phase II data forzilebesiran(hypertension in patients at high risk of cardiovascular disease) and additional positive phase II data forfenebrutinib(multiple sclerosis)Positive longer-term efficacy and safety data forOcrevus(multiple sclerosis) andVabysmo (retinal vein occlusion, a severe eye disease)Launch of first validated test for earlierdiagnosis of neonatal sepsis and new module toimprove laboratory efficiencyOutlook for 2023 confirmedRoche CEO Thomas Schinecker: “We achieved good results in the first nine months of 2023, more than compensating for the expected decline in demand for COVID-19 products. Our Group sales excluding COVID-19 products continued to grow strongly by +9% at constant exchange rates. Additionally, we mad...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: African Health | Age-Related Macular Degeneration (AMD) | Appendicitis | Avastin | Babies | Biotechnology | Bladder Cancer | Brain | Brain Cancers | Brazil Health | Breast Conservation Surgery | Canada Health | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemistry | Chemotherapy | China Health | Clinical Trials | COVID-19 | Diabetes | Disability | Emergency Medicine | Endocrinology | France Health | Gastric (Stomach) Cancer | Gastroenterology | Germany Health | Government | Haemophilia | Heart | Hemophilia | Herceptin | History of Medicine | Hypertension | Immunotherapy | India Health | Influenza | Japan Health | Laboratory Medicine | Liver | Lung Cancer | Marketing | Men | Middle East Health | Multiple Sclerosis | Neurology | Neuroscience | Neurosurgery | Non-Small Cell Lung Cancer | Oral Cancer | Oseltamivir | Pathology | Perinatology & Neonatology | Pharmaceuticals | Pregnancy | Profits and Losses | Rheumatology | Rituxan | Russia Health | Skin | Skin Biopsy | Spinal Muscular Atrophy | Study | Switzerland Health | Tamiflu | UK Health | Urology & Nephrology | USA Health | Vitamin A | Women | Xeloda